Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -33.2% | -36.6% | 55.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 77.3% | 80.1% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,582.1% | -588.4% | -339% | -524.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,656.3% | -636.1% | -368.5% | -556.8% |
| EPS Diluted | -5.81 | -7.49 | -13.84 | -18.25 |
| % Growth | 22.4% | 45.9% | 24.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |